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Objective: Several hundreds of CFTR variants have been reported, it is not known
whether they are causing CF or not. M470 and the combined V frequency is seen the
sub-Saharian Africa. In this study, we aimed to investigate the clinical importance
of M470V mutation in Antiochia region (ancient commercial center and capital of
Syria; an early center of Christianity) which is in the vicinity of Africa and a region
with frequent consanguineous marriages due to ethnical reasons.
Method: The study was designed as a case control study. The study group consisted
of 79 children with mutations out of 145 children who were undergoing CF gene
study because of recurrent respiratory tract infections, growth failure, chronic
diarrhea and constipation. These 79 patients’ clinical and labarotory features were
investigated.
Results: In 63 of 145 patients (43.4%), heterozygous mutation, in 16 (11%)
homozygous mutation was detected. Mean age of those patients was 41.21±39.8
(min: 6 max: 192) months and 30 (38%) were girls and 49 (62%) were boys. All
of them had M470V mutation. Of the patients with mutation 17 (32.7%) had a
familial history of cystic ﬁbrosis, 2 had sibling death history. In mutation group,
only annual number of infections, skin dryness, loss of weight, level of IgG and
IgM were signiﬁcantly higher (p< 0.05).
Conclusion: It was concluded that in M470V positive cases, the disease may cause
clinical symptoms without affecting sweat test results, with less gastrointestinal but
more respiratory symptoms, causing a more prominent loss of weight, and causing
higher levels of immunoglobulin due to more frequent infections.
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Objectives: Cystic ﬁbrosis (CF) homozygous F508del mutation is classically char-
acterized by earlier clinical presentation, more severe disease and more rapid clinical
decline. The aim of this study was to determine the prevalence of that genotype in
northern Portugal and compare their clinical features with other mutations.
Methods: Retrospective cohort analysis based on data collected from the two
reference centers treating pediatric patients in that region. Multiple variables
were analyzed as age, sex, CFTR genotype, age and body mass index (BMI)
at the time of the CF diagnosis, BMI at the time of data collection, pancreatic
insufﬁciency, percent predicted FEV1 (FEV1%) and microbiologic agents. The
population obtained was then separated in two groups based in genotype mutation,
group 1, F508del homozygous and group 2, with other mutations.
Results: 71 patients were obtained, with a median age of 10.5 years [0.72; 23.2], 37
(52%) included in group 1 (19 males) and 34 (48%) in group 2 (14 males). The age
of CF diagnosis and the BMI at the time of data collection were signiﬁcant lower
in the ﬁrst group (p = 0.025 and p = 0.015, respectively). Pancreatic insufﬁciency
was more frequent in group 1 (p = 0.013). Pseudomonas aeruginosa was also found
more frequently in the homozygous F508del patients (p = 0.013). There was no
signiﬁcant difference between the two groups when analyzed de BMI at the time
of the CF diagnosis and the FEV1%.
Conclusion: CF diagnosis was earlier, the BMI at the time of data collection was
lower, pancreatic insufﬁciency was more frequent and the Pseudomonas aeruginosa
was isolated more often in the population with homozygous F508del mutation.
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Objectives: To collect further data to conﬁrm the high Cystic Fibrosis (CF)
prevalence in the Albanian population in Tuscany (Italy). CF is common in Albania
but there are no data about its incidence in this country. In 1992 there was a
great immigration of Albanians to Tuscany. In our previous study we analyzed the
number of Albanians born in Tuscany over a 10-yr period (1991–2001) who were
screened for CF. In that period there were 1803 Albanian newborns and 4 CF cases
were diagnosed by newborn screening (NBS) with incidence 1:450. These data
suggested that the incidence of CF in the Albanian population is high, but they
were not enough to be conclusive.
Materials: The Regional CF Center for Tuscany has been screening newborns of
the Region since 1992. We compared the prevalence of Albanian patients affected
by CF to the total Albanian population living in Tuscany and to the prevalence of
CF patients of Italian origin living in this area.
Tuscany is a region of 3,749,813 of inhabitants; the immigrant population has
increased from 2% in 2002 to 10% in 2011; 17% of immigrants are of Albanian
nationality, numbering 68,333. The overall CF incidence is about 1:3800, basically
stable for the last 20 ys. The Regional CF Center follows 283 patients, 15 are
Albanian: 8 diagnosed by NBS screening, 3 by meconium ileus and 4 by symptoms
because they arrived in our region after birth. The prevalence of Albanian patients
affected by CF among Albanians living in Tuscany is 2.1/1000; the prevalence of
CF patients among the Italian population living in Tuscany (3,385,661) is 0.08/1000.
Conclusion: These data conﬁrm previous reports: high prevalence of CF among
Albanians.
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Objectives: The life expectancy of CF patients continues to improve over the last
decade. According to the CF Trust 2010 Annual Report, the median age at death in
years was 24 in 2007 and 29 in 2010. However, the impact of widespread genetic
testing in identifying older patients with ‘mild phenotypes’ on this trend is unknown.
Methods: Data of all patients within the UK CF registry born before 2011 who are
alive at some point between 2007 and 2010 were obtained. Patients were divided
into two categories of ‘mild phenotypes’ (diagnosed when older than 18 years, i.e.
‘late’ diagnosis, pancreatic sufﬁcient) and ‘typical CF’ (‘early’ diagnosis, pancreatic
insufﬁcient). Kruskal-Wallis test was used to compare the overall, ‘mild phenotype’
and ‘typical CF’ median age at death from 2007 to 2010.
Results: See the table.
Table: Median age at death of CF patients, from 2007 to 2010
Category Median age at death, years (inter-quartile range)
2007 2008 2009 2010 Kruskal–Wallis test
p-value
Overall 25.0 (10) 26.5 (14) 27.0 (15) 29.0 (16) 0.084
‘Early diagnosis’ 25.0 (10) 26.0 (12) 27.0 (14) 28.5 (15) 0.062
Pancreatic insufﬁcient 25.0 (10) 26.0 (13) 27.0 (14) 30.0 (15) 0.038
Pancreatic sufﬁcient 27.5 (range = 7) 43.0 (35) 48.5 (31) 25.0 (18) 0.338
Conclusion: The improvement in the median age at death for ‘typical CF’ patients who
were diagnosed ‘early’ or pancreatic insufﬁcient mirrored the overall improvement. The
overall survival improvement persisted when the analysis excluded ‘mild phenotype’
(pancreatic sufﬁcient or ‘late’ diagnosis) patients.
It is therefore unlikely for the overall improvement in median age at death to be driven
by increased case ﬁnding of mild phenotypes. Further analyses are being undertaken
to understand the temporal incidence and prevalence trend among ‘mild phenotypes’
CF patients.
We thank the UK CF Registry for supplying the data for this analysis.
